Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has accepted its new drug application (“NDA”) for vanza triple therapy for treating people with cystic fibrosis (“CF”) aged six years and above. The company is seeking FDA’s nod for vanza triple in CF aged six years and older who have at least one F508del mutation or another responsive mutation in the CF transmembrane conductance regulator (CFTR) gene responsive to the vanza triple. Vanza triple is a combination of vanzacaftor, a CFTR potentiator, deutivacaftor, a CFTR corrector and tezacaftor. Vanza triple is a new once-a-day oral combination medicine that has the potential for enhanced patient benefit than Trikafta patients and can potentially treat CF patients who have discontinued Trikafta or other Vertex CF medicines. It can also improve dosing (once daily) and lower the royalty burden. With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on Jan 2, 2025. Simultaneously, the European Medicines Agency has also validated the marketing authorization application for vanza triple for CF patients aged six years and older. VRTX filed regulatory applications for vanza triple for treating people with CF aged six years and older using a priority voucher in the United States and in the European Union in May. Shares of Vertex have rallied 16.5% so far this year against the industry’s decline of 6.3%. Zacks Investment Research Image Source: Zacks Investment Research VRTX has also submitted regulatory filings for vanza triple in Canada, Australia, Switzerland and the United Kingdom. Vertex holds a dominant position in the CF market. The company’s CF sales continue to grow, driven by its triple therapy, Trikafta (marketed as Kaftrio in Europe). Trikafta/Kaftrio generated revenues of $2.48 billion in the first quarter of 2024, up 18.5% on a year-over-year basis. Sales are being driven by the continued robust performance of the drug in and outside the United States, fueled by label expansions to younger age groups. A potential approval for vanza triple is likely to boost Vertex’s CF franchisee sales further in 2024 and beyond. Zacks Rank & Stocks to Consider Vertex currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector are Acrivon Therapeutics, Inc. ACRV, Aligos Therapeutics, Inc. ALGS and RAPT Therapeutics, Inc. RAPT, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Acrivon Therapeutics’ 2024 loss per share have narrowed from $3.05 to $2.47. Loss per share estimates for 2025 have narrowed from $3.04 to $2.55. Year to date, ACRV shares have rallied 23.6%. ACRV’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining one occasion, the average surprise being 3.56%. In the past 60 days, estimates for Aligos Therapeutics’ 2024 loss per share have narrowed from 84 cents to 73 cents, while loss per share estimates for 2025 have narrowed from 82 cents to 71 cents. Year to date, ALGS shares have declined 39.8%. Aligos’ earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, the average surprise being 7.83%. In the past 60 days, estimates for RAPT Therapeutics’ 2024 loss per share have narrowed from $3.19 to $2.93. Loss per share estimates for 2025 have narrowed from $2.40 to $2.05. Year to date, RAPT shares have declined 88.8%. RAPT’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 3.19%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX):Free Stock Analysis Report Rapt Therapeutics (RAPT):Free Stock Analysis Report Aligos Therapeutics, Inc. (ALGS):Free Stock Analysis Report Acrivon Therapeutics, Inc. (ACRV):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...